Fulgent (FLGT) Q2 Revenue Jumps 16%

Fulgent Genetics reported stronger-than-expected Q2 2025 results, with GAAP revenue of $81.8 million and non-GAAP earnings per share of $0.07, significantly surpassing analyst estimates of $76.21 million and a $(0.18) loss, respectively. The company raised its full-year 2025 core revenue guidance to $320 million, primarily driven by robust growth in its Laboratory Services segment. Despite this top-line outperformance and strong cash position, the quarter saw a wider GAAP loss due to a one-time impairment, with the company still projecting a full-year GAAP loss as it balances growth with rising operating expenses and strategic investments.

Analysis

Fulgent Genetics (FLGT) delivered a strong Q2 2025 performance on the top line, with GAAP revenue of $81.8 million surpassing the $76.2 million consensus estimate, driven by 16% year-over-year growth in its core Laboratory Services business. This outperformance, fueled by momentum in reproductive health and new client contracts, prompted management to raise its full-year 2025 core revenue guidance to $320 million. The company also significantly beat earnings expectations, posting a non-GAAP EPS of $0.07 versus an anticipated loss of $(0.18). However, this positive non-GAAP result marks a 53.3% decline from the prior year, and profitability remains a key challenge. The company's GAAP loss widened due to a $9.9 million one-time asset impairment, and the adjusted EBITDA loss increased to $3.0 million. These figures reflect rising operating expenses tied to strategic investments in digital pathology, AI-driven workflows, and clinical trials for its therapeutic pipeline. The company maintains a robust financial position with $777.5 million in cash and investments, enabling continued share repurchases and funding for its long-term therapeutic development segment, though it still projects a GAAP loss of $(2.10) per share for the full year.

Key Decisions for Investors

• Investors should recognize the strong execution in the core diagnostics business, validated by the revenue beat and raised guidance, as the primary near-term value driver.
• It is critical to scrutinize the path to profitability by monitoring operating expense trends and adjusted EBITDA, as the current growth is funded by a strong balance sheet rather than operational profit.
• The substantial $777.5 million cash position supports long-term therapeutic R&D and capital returns, but investors should weigh the pace of cash burn against progress in the clinical pipeline.
• Key risks to monitor include potential regulatory changes affecting laboratory-developed tests and the company's ability to gain operating leverage as it scales.